Vanda Pharmaceuticals Inc. (VNDA): Free Cash Flow
-$110.44M
Year ended 2025-12-31
-$143.00M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$110.44M | n/m | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | -$16.25M | n/m | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $12.42M | -60.3% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $31.30M | -50.8% | 2025-02-14, From 2022-01-01 |
| 2021-12-31 | $63.66M | +27.4% | 2024-02-08, From 2021-01-01 |
| 2020-12-31 | $49.98M | +11.2% | 2023-02-09, From 2020-01-01 |
| 2019-12-31 | $44.93M | +51.7% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $29.62M | n/m | 2021-02-11, From 2018-01-01 |
| 2017-12-31 | -$3.65M | n/m | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | -$9.51M | n/m | 2019-02-19, From 2016-01-01 |
| 2015-12-31 | $9.92M | n/m | 2018-02-15, From 2015-01-01 |
| 2014-12-31 | -$82.32M | n/m | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | -$39.77M | n/m | 2016-02-12, From 2013-01-01 |
| 2012-12-31 | -$46.93M | n/m | 2015-03-13, From 2012-01-01 |
| 2011-12-31 | -$28.68M | n/a | 2014-02-25, From 2011-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$110.44M | n/m |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | -$73.47M | n/m |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $41.73M | +7.4% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $19.61M | n/m |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $67.70M | n/m |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $105.95M | n/m |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$116.63M | n/m |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$484.00M | n/m |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | -$70.72M | n/m |
Compare VNDA, IDYA, PBYI, ANAB side by side · Screen every company in Pharmaceutical Preparations ↗